Pharmaceutical

Genentech eyes lupus market for Gazyva with positive Phase III data readout  

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU.

Feb 9, 2025 - 06:00
Genentech eyes lupus market for Gazyva with positive Phase III data readout  
Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU.
Read the original article

Tags:

Previous Article

43rd Annual JP Morgan Healthcare Conference 2025 OR

Next Article

How AI is streamlining cell and gene therapy manufacturing

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: How biotech deal-making really works behind the scenes, according to founders

STAT+: How biotech deal-making really works behind the ...

Oct 20, 2023

STAT+: In setback, Pfizer abandons one weight loss pill and bets on another

STAT+: In setback, Pfizer abandons one weight loss pill...

Jun 26, 2023

Sensorion raises $16m for gene therapies to treat deafness

Sensorion raises $16m for gene therapies to treat deafness

Apr 9, 2024